Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Abstract Text:

This study compared the effects on blood pressure and some metabolic variables of a 3-month period addition therapy of urapidil or metoprolol in 273 hypertensive non-responders to nifedipine sustained release (SR) monotherapy. This was a randomised, open-label, controlled, parallel-group comparative study, followed by another 3-month period during which all patients received the combination nifedipine SR-urapidil independently of the treatment they were previously randomized to. Both treatments caused significant falls in systolic (SBP) and diastolic blood pressure (DBP) when compared with the nifedipine SR monotherapy phase. The addition of urapidil to nifedipine SR caused a significant blood pressure reduction of 16.6/13.6 mmHg (p < 0.001), whereas after metoprolol the decrease was of 15.1/14 mmHg (p < 0.001). While in the overall population there was no statistically significant difference between the reduction caused by the two antihypertensive agents added to nifedipine SR, significant differences (DBP, p < 0.05; SBP, p < 0.01) were observed in the group of 51 patients aged at least 60 years. Total cholesterol and LDL-cholesterol were significantly reduced (p < 0.001) after the addition of urapidil to nifedipine SR, while, on the contrary, the addition of metoprolol to nifedipine SR was followed by a significant rise (p = 0.001). The changes caused by the two agents were statistically different among them (p < 0.01). The non-atherogenic HDL-cholesterol did not change during the addition of urapidil or metoprolol to nifedipine SR, while, the HDL/total cholesterol ratio was significantly increased after the addition of urapidil (p < 0.01) and unmodified after the addition of metoprolol. Between-group analysis showed a significant difference (p = 0.005). Serum triglycerides did not change in the urapidil plus nifedipine SR group but significantly increased in the metoprolol plus nifedipine SR group (p < 0.001); between-group difference was not statistically significant. Plasma glucose was unchanged after the addition of urapidil whereas it was significantly (p < 0.001) increased in the metoprolol-added group with a between-group difference statistically significant (p < 0.05). When metoprolol was substituted by urapidil during the second 3-month period, the negative effects on glucose, total cholesterol, LDL cholesterol and triglycerides were abolished while in the group already treated with urapidil plus nifedipine SR the favourable effects of urapidil plus nifedipine SR on total cholesterol, LDL-cholesterol and HDL/total cholesterol ratio were significantly increased compared with the end of the first 3-month treatment. The results of this study show that when urapidil and metoprolol are added to non-responders to nifedipine SR therapy there is a clinically and statistically relevant blood pressure reduction with both agents, with a therapeutic advantage for the combination urapidil + nifedipine SR in patients more than 60 years old. Moreover, the addition of urapidil was associated with a more favourable effect on serum lipids and glucose than that produced by the addition of metoprolol.

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Publishing Authors By Initials

For similar heterocyclic compounds: heterocyclic compounds, 1-ring: piperazines research abstracts see: heterocyclic compounds: heterocyclic compounds, 1-ring: piperazines research

PUBMED ID PMID:

MEDLINE DATE:

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Blood pressure. Supplement

VOLUME: 3

Page Numbers: 38-46

Journal Abbreviation:

ISSN: 0803-8023

DAY: 26

MONTH: 02

YEAR: 1995

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9300787

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Keywords Mesh Terms:

KEYWORDS: Piperazines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Information

Substance Name: Metoprolol

Registry Number: 37350-58-6

Grant and Affiliation Information for Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.

AFFILIATION: Centro di Fisiologia Clinica e Ipertensione, Ospedale Maggiore, Milano.

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood Press Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects Italian Urapidil Study Group Related Publications

• Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
• Antihypertensive therapy in patients above age 60 with systolic hypertension. A progress report of the European Working Party on High Blood Pressure in the Elderly (EWPHE).
• Cardiac, renal and vascular complications in the diabetic patient.
• Cardiovascular consequences of hypertension: therapeutic effects on organ damage and on cardiovascular events.
• Cardiovascular effects of afferent renal nerve stimulation.
• Carotid baroreceptor reflex in normotensive and hypertensive subjects.
• Characteristics of an ideal antihypertensive therapy for elderly hypertensives.
• Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage.
• Comparative measurements of immunoreactive renin, plasma renin activity and angiotensin II in human plasma.
• Differences in reflex control of arterial pressure and renin release during head-up tilting in the cat.
• Editing a scientific journal: problems and challenges.
• Evaluation of a new non-invasive semiautomatic blood pressure monitoring device.
• Factors influencing the carotid baroreceptor response to pressure changes in a neck chamber.
• Hemodynamic and neural effects of urapidil and prazosin in essential hypertensives.
• Interplay of sino-aortic reflexes and haemodynamic changes during natural sleep in the cat.
• Introduction.
• Left ventricular hypertrophy regression with antihypertensive treatment: focus on Candesartan.
• Mechanisms of blood pressure variability in man.
• Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study.
• Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atheroscelerosis (ELSA).
• Relationship between the hypotensive and renin-stimulating actions of diuretic therapy in hypertensive patients.
• Renin release and renal vasomotor changes during stimulation of the brain stem in the cat.
• Role of the renal nerves in renin release during suprarenal aortic stenosis in cats.
• Target blood pressure in elderly hypertensive patients: how low should you go?
• The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence.
• The sympathetic nervous system in human hypertension.
• Time course of the changes in active and cryoactivatable renin in response to acute stimuli before and after diuretic therapy in man.
• Urapidil in hypercholesterolemic hypertensive patients.
• Value of echocardiographic and ambulatory blood pressure monitoring in hypertension.
• [Not Available.]